Boston-based Dewpoint Therapeutics and Merck will collaborate to develop a novel mechanism for the treatment of HIV by harnessing Dewpoint’s proprietary platform for condensate-based drug discovery.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.

The COVID-19 pandemic underscored weaknesses in critical industries in the U.S. In the pharmaceutical industry, the global nature of the business, long considered a benefit, became not just a weakness but a national security threat.

Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.

Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway.

Although the trial failed to meet the primary endpoint of PFS, the data for overall survival as a co-primary endpoint is not yet mature. The company plans to continue the trial until the next planned analysis.

Angelman Syndrome is a genetic disorder that mostly affects the nervous system.

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo).

Even before a vaccine for the novel coronavirus has been completely developed, nations across the globe are jockeying for position to lay claim for the potential preventative medicine in something of a healthcare arms race.

Biogen announced on Wednesday that it has seen positive results from its Phase I/II study of tofersen, also known as BIIB067, for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

Gilead Sciences reported additional data from its Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.

Blackstone announced its Blackstone Life Sciences V fund closed at its hard cap of $4.6 billion of total capital commitments, making it the largest life sciences private fund that has been raised to date.

BioNTech Chief Executive Officer Ugur Sahin predicts the company’s vaccine for COVID-19, which is it co-developing with Pfizer, could be ready for regulatory approval by the end of the year, with hundreds of millions of doses available for immediate distribution.

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.

Researchers at the University of California, San Francisco, working with mice, found that by taking blood from mice that exercised regularly and giving it to “couch potato” mice, re-energized the brains of the non-active mice.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Reltecimod is a synthetic peptide antagonist of both superantigen exotoxins and the CD28 T-cell costimulatory receptor.

Cancer patients aren’t getting the testing they need for precision medicine, partially because of pervasive confusion regarding terminology, according to a whitepaper released July 7 by the Consistent Testing Terminology Working Group.

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding that wholesale bans on trade can affect community livelihoods and food security, the pandemic underscores the need for widespread pathogen screening and monitoring to better understand, predict and contain outbreaks in wildlife and humans.